Artemis Medicare Services working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

16.82×	16.82×	16.10×	20.09×	24.71×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
37.29×	37.29×	38.21×	39.07×	41.25×
143.48×	143.48×	156.98×	152.49×	138.74×
−89.37×	−89.37×	−102.67×	−93.33×	−72.78×
7.14×	6.93×	2.90×	−193.14×	−20.81×
0.78×	0.78×	0.80×	0.94×	0.91×
1.27×	1.27×	1.77×	2.21×	3.35×
0.70×	0.70×	0.96×	0.82×	1.35×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ARTEMISMED₹297.95

Artemis Medicare Services Limited

· Pharma & Health

₹ CrorePeersINDRAMEDCO SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹4,717 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	24.71	20.09	16.10	16.82	16.82
Receivable Days (DSO)	41.25	39.07	38.21	37.29	37.29
Payable Days (DPO)	138.74	152.49	156.98	143.48	143.48
Cash Conversion Cycle (days)	-72.78	-93.33	-102.67	-89.37	-89.37
Working Capital Turnover	-20.81	-193.14	2.90	6.93	7.14
Asset Turnover	0.91	0.94	0.80	0.78	0.78
Cash Conversion (CFO/Net Income)	3.35	2.21	1.77	1.27	1.27
CFO/EBITDA	1.35	0.82	0.96	0.70	0.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.